GlassScriptPhysician profile
Edmond A Bendaly
NPI 1285835652
$43,129.53
in general payments reported to CMS, 2019-2025
62 companies · $8,396 in 2025
The $8,396 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,241 · 2020: $10K · 2021: $3,725 · 2022: $2,366 · 2023: $6,387 · 2024: $6,651 · 2025: $8,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $6,819 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,408.00 |
| Food and Beverage | $6,819.35 |
| Education | $206.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,114.26 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $8,833.78 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Taiho Oncology, INC. | $2,640.00 | 2023 | |
| Glaxosmithkline, LLC. | $2,012.12 | 2021-2025 | Zejula |
| Lilly USA, LLC | $1,943.39 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| Beone Medicines USA, INC. | $1,833.00 | 2025 | Brukinsa |
| Kite Pharma, INC. | $1,736.59 | 2020-2025 | Yescarta |
| Seagen INC. | $1,392.21 | 2022-2023 | Padcev, Tukysa |
| Rigel Pharmaceuticals, INC. | $1,200.00 | 2020 | |
| Exelixis INC. | $1,078.24 | 2020-2025 | Cabometyx |
| Pfizer INC. | $911.57 | 2019-2025 | |
| Daiichi Sankyo INC. | $859.18 | 2022-2025 | Vanflyta, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $839.74 | 2019-2025 | |
| Janssen Biotech, INC. | $696.13 | 2019-2025 | Tecvayli, Darzalex, Imbruvica |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmond Bendaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.